Characterization of BI 6727, a novel Polo-like kinase inhibitor with a distinct pharmacokinetic profile and efficacy in a model of taxane-resistant colon cancer

被引：0
|
作者：
Blagden, S. [1 ]
Olmos, D. [2 ]
Sharma, R. [1 ]
Barruiso, J. [2 ]
Medani, H. [1 ]
Versola, M. [3 ]
Murray, S. [3 ]
Smith, D. A. [3 ]
Dar, M. M. [3 ]
deBono, J. S. [2 ]
机构：
[1] Univ London Imperial Coll Sci Technol & Med, Dept Oncol, London, England
[2] Royal Marsden Hosp, Drug Dev Unit, Sutton, Surrey, England
[3] GlaxoSmithKline Inc, Res & Dev, Res Triangle Pk, NC USA
来源：
EJC SUPPLEMENTS | 2008年 / 6卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：135 / 135
页数：1
相关论文
共 45 条
  • [41] An open-label, phase II study of the polo-like kinase-1 (P1k-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC)
    Awad, Mark M.
    Chu, Quincy S-C
    Gandhi, Leena
    Stephenson, Joe J.
    Govindan, Ramaswamy
    Bradford, Daniel S.
    Bonomi, Philip D.
    Ellison, David M.
    Eaton, Keith D.
    Fritsch, Holger
    Munzert, Gerd
    Johnson, Bruce E.
    Socinski, Mark A.
    LUNG CANCER, 2017, 104 : 126 - 130
  • [42] Phase I/II Study of Volasertib (BI 6727), An Intravenous Polo-Like Kinase (Plk) Inhibitor, in Patients with Acute Myeloid Leukemia (AML): Updated Results of the Dose Finding Phase I Part for Volasertib in Combination with Low-Dose Cytarabine (LD-Ara-C) and As Monotherapy in Relapsed/Refractory AML
    Bug, Gesine
    Mueller-Tidow, Carsten
    Schlenk, Richard F.
    Kraemer, Alwin
    Luebbert, Michael
    Krug, Utz
    Voss, Florian
    Taube, Tillmann
    Fritsch, Holger
    Garin-Chesa, Pilar
    Ottmann, Oliver G.
    Doehner, Hartmut
    BLOOD, 2011, 118 (21) : 673 - 673
  • [43] Phase I/II Study of Volasertib (BI 6727), an Intravenous Polo-Like Kinase (Plk) Inhibitor, in Patients with Acute Myeloid Leukemia (AML): Results From the Randomized Phase II Part for Volasertib in Combination with Low-Dose Cytarabine (LDAC) Versus LDAC Monotherapy in Patients with Previously Untreated AML Ineligible for Intensive Treatment
    Maertens, Johan
    Luebbert, Michael
    Fiedler, Walter
    Fouillard, Loic
    Haaland, Alf
    Brandwein, Joseph M.
    Lepretre, Stephane
    Reman, Oumedaly
    Turlure, Pascal
    Bug, Gesine
    Mueller-Tidow, Carsten
    Kraemer, Alwin
    Voss, Florian
    Taube, Tillmann
    Fritsch, Holger
    Doehner, Hartmut
    BLOOD, 2012, 120 (21)
  • [44] Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)
    Schoffski, Patrick
    Blay, Jean-Yves
    De Greve, Jacques
    Brain, Etienne
    Machiels, Jean-Pascal
    Soria, Jean-Charles
    Sleijfer, Stefan
    Wolter, Pascal
    Ray-Coquard, Isabelle
    Fontaine, Christel
    Munzert, Gerd
    Fritsch, Holger
    Hanft, Gertraud
    Aerts, Claire
    Rapion, Jerome
    Allgeier, Anouk
    Bogaerts, Jan
    Lacombe, Denis
    EUROPEAN JOURNAL OF CANCER, 2010, 46 (12) : 2206 - 2215
  • [45] Multicenter parallel phase II trials of the polo-like kinase 1 inhibitor BI-2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organisation for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)
    Schoeffski, P.
    Blay, J. Y.
    De Greve, J.
    Brain, E.
    Machiels, J. P.
    Soria, S. C.
    Sleijfer, S.
    Munzert, G.
    Rapion, J.
    Lacombe, D.
    EJC SUPPLEMENTS, 2009, 7 (02): : 138 - 139
12345